Location History:
- Vaulanaveys le Haut, FR (2014)
- Valbonne, FR (2019)
Company Filing History:
Years Active: 2014-2019
Title: Frederic Pilotaz: Innovator in Ophthalmic Solutions
Introduction
Frederic Pilotaz is a notable inventor based in Valbonne, France. He has made significant contributions to the field of ophthalmology, particularly in the development of pharmaceutical compositions aimed at treating viral eye infections. With a total of 2 patents, his work reflects a commitment to advancing medical treatments.
Latest Patents
One of Frederic Pilotaz's latest patents is a composition effective against viral conjunctivitis. This invention relates to a pharmaceutical composition designed for the prophylactic or therapeutic topical treatment of viral eye infections caused by adenovirus of subtype D or influenza A virus of subtype H7. The composition is formulated with iota carrageenan as the active antiviral ingredient and is substantially free of metal halide salts or contains no more than 0.5% w/v of such salts. Another significant patent is a preservative-free prostaglandin-based ophthalmic solution. This solution is notable for being free of antimicrobial preservatives and includes at least one prostaglandin as the active substance, along with polyoxyl-15-hydroxystearate as a solubilizing agent.
Career Highlights
Frederic Pilotaz has worked with prominent companies in the pharmaceutical industry, including Laboratoires Thea and Nicox S.A. His experience in these organizations has allowed him to develop innovative solutions that address critical health issues.
Collaborations
Throughout his career, Frederic has collaborated with esteemed colleagues such as Fabrice Mercier and Henri Chibret. These partnerships have contributed to the successful development of his inventions and have enhanced the impact of his work in the field.
Conclusion
Frederic Pilotaz stands out as an influential inventor in the realm of ophthalmic solutions. His innovative patents and collaborations reflect his dedication to improving treatments for viral eye infections. His contributions continue to shape the future of ophthalmology.